The effects of chromium supplementation on serum glucose and lipids in patients with and without non-insulin-dependent diabetes

• Published in: Metabolism, clinical and experimental Vol. 41; no. 7; p. 768
• Main Authors: Abraham, A.S. (Shaare Zedek Medical Center, Jerusalem, Israel), Brooks, B.A, Eylath, U
• Format: Journal Article
• Language: English
• Published: United States 01.07.1992
• Subjects: ADDITIF ALIMENTAIRE; ADITIVOS ALIMENTARIOS; Adult; Aged; Aged, 80 and over; ARTERIOSCLEROSE; ARTERIOSCLEROSIS; Arteriosclerosis - drug therapy; ATHEROSCLEROSIS; Blood Glucose - analysis; BLOOD LIPIDS; BLOOD SERUM; Cholesterol, HDL - blood; CHROME; CHROMIUM; Chromium - blood; Chromium - pharmacology; Chromium - therapeutic use; CROMO; DIABETE; DIABETES; DIABETES MELLITUS; Diabetes Mellitus, Type 2 - blood; Female; FOOD ADDITIVES; GLUCOSA; GLUCOSE; Humans; LIPAEMIA; LIPEMIA; LIPEMIE; Lipids - blood; Male; Middle Aged; SERUM SANGUIN; SUERO SANGUINEO
• ISSN: 0026-0495; 1532-8600
• DOI: 10.1016/0026-0495(92)90318-5

Seventy-six patients with established atherosclerotic disease were treated daily with either 250 micrograms of chromium orally as chromium chloride or a placebo for a period of 7 to 16 months (mean, 11.1 months). Serum chromium increased from 2.69 +/- 0.09 to 12.12 +/- 0.77 nmol/L (mean +/- SE, P less than .005). Serum triglycerides were lower (1.68 +/- 0.11 and 2.10 +/- 0.14 nmol/L, respectively; P less than .02) in the chromium-treated patients than in the patients who received placebo, and serum high-density lipoprotein (HDL) increased (from 0.94 +/- 0.05 to 1.14 +/- 0.07 mmol/L, P less than .005) in the patients who received chromium. There was no change in serum cholesterol or blood glucose during the study.